Executive Summary
Adroit Healthcare Services provide the comprehensive list of PD-1 and PD-L1 antibodies that are marketed for different indications and the products that are in development. The main objective of this report is to provide a comprehensive secondary research and market analysis of anti-CD19 antibody pipeline products that are in Phase 3, Phase 2, Phase 1, preclinical and discovery across different indications. This report also provides comprehensive research on the companies that are working on anti-CD19 antibody including the deals and acquisitions.
Report Coverage:
- Clinical (Phase Products)
- Non-clinical (Preclinical and Discovery)
- Dormant and Discontinued
- Technology
- Collaboration details
Companies Mentioned
Bristol-Myers Squibb, Merck & Co., CureTech, AstraZeneca, ImmunOs Therapeutics, Regeneron Pharmaceuticals, Novartis Pharmaceuticals,
Request Sample Report @ https://www.wiseguyreports.com/sample-request/3271726-pd-1-pd-l1-pipeline-analysis-2018
Table of Content:
Executive Summary
Programmed Death 1 (PD-1)
Programmed Death Ligand 1 (PD-L1)
- Description and MOA of PD-1 and PD-L1 pathways
- Significance of PD-1 and PD-L1 inhibitors
- Therapy Areas related to PD-1 and PD-L1
- Biomarkers – PD-1 and PD-L1 inhibitors
Competitive Landscape
- Market Overview
- Marketed Drug Candidate Profiles
- Marketed Drugs Sales
- Details of Patent Expiry of Marketed Drugs
Current and Future Market for PD and PD-L1 inhibitors
Challenges and Barriers associated with use of PD and PD-L1 inhibitors
PD-1/PD-L1 Combinations Profiles
Pipeline Therapeutics
Therapeutics under Development by Companies
Late State Products
- Product Description
- Research and Development
- Product Development Activities
Mid Stage Products
- Product Description
- Research and Development
- Product Development Activities
Early Stage Products
- Product Description
- Research and Development
- Product Development Activities
Preclinical & Discovery
- Product Description
- Research and Development
- Product Development Activities
Therapeutic Assessment
- Assessment by Route of Administration
- Assessment by Phase & Route of Administration
- Assessment by Molecule Type
- Assessment by Phase & Molecule type
Collaborations and Acquisitions Details
Dormant Products
Discontinued Products
Appendix
Methodology
Disclaimer
Table 1: Marketed and Pipeline PD-1 and PD-L1 drugs, 2018
Table 2: Sales of Marketed drugs, 2018
Table 3: Patent expiration details – marketed drugs, 2018
Table 4: Number of Products Under Development for PD-1 and PD-L1 inhibitors Drugs, 2018
Table 5: Products under Development by Companies, 2018
Table 6: Late Stage Products, 2018
Table 7: Mid Stage Products, 2018
Table 8: Early Stage Products, 2018
Table 9: Pre-Clinical and Discovery Products, 2018
Table 10: Assessment by Route of Administration, 2018
Table 11: Assessment by Stage and Route of Administration, 2018
Table 12: Assessment by Molecule Type, 2018
Table 13: Assessment by Stage and Molecule Type, 2018
Table 14: Comparative Analysis
Table 15: Dormant Products
Table 16: Discontinued Products
Figure 1: Marketed and Pipeline PD-1 and PD-L1 drugs, 2018
Figure 2: Sales of Marketed drugs, 2018
Figure 3: Patent expiration details – marketed drugs, 2018
Figure 4: Number of Products Under Development for PD-1 and PD-L1 inhibitors Drugs, 2018
Figure 5: Products under Development by Companies, 2018
Figure 6: Late Stage Products, 2018
Figure 7: Mid Stage Products, 2018
Figure 8: Early Stage Products, 2018
Figure 9: Pre-Clinical and Discovery Products, 2018
Figure 10: Assessment by Route of Administration, 2018
Figure 11: Assessment by Stage and Route of Administration, 2018
Figure 12: Assessment by Molecule Type, 2018
Figure 13: Assessment by Stage and Molecule Type, 2018
Figure 14: Comparative Analysis
Figure 15: Dormant Products
Figure 16: Discontinued Products
Continuous…
For further information on this report, visit – https://www.wiseguyreports.com/reports/3271726-pd-1-pd-l1-pipeline-analysis-2018
Media Contact
Company Name: Wiseguyreports.com
Contact Person: Norah Trent
Email: Send Email
Phone: +1 646 845 9349, +44 208 133 9349
City: Pune
State: Maharashtra
Country: India
Website: www.wiseguyreports.com